134
Participants
Start Date
January 24, 2012
Primary Completion Date
March 10, 2014
Study Completion Date
March 10, 2014
Ranolazine
Tablets administered orally twice daily.
Dronedarone
Capsule administered orally twice daily
Ranolazine placebo
Tablets administered orally twice daily.
Dronedarone placebo
Capsules administered orally twice daily
Investigational Site, Utica
Investigational Site, Afula
Investigational Site, Washington D.C.
Investigational Site, Takoma Park
Investigational Site, Towson
Investigational Site, Como
Investigational Site, Nahariya
Investigational Site, Haifa
Investigational Site, Lakeland
Investigational Site, Göttingen
Investigational Site, Hadera
Investigational Site, Cleveland
Investigational Site, Florence
Investigational Site, Bonn
Investigational Site, Wausau
Investigational Site, Holon
Investigational Site, Frankfurt
Investigational Site, Rehovot
Investigational Site, Houston
Investigational Site, Ashkelon
Investigational Site, Aurora
Investigational Site, München
Investigational Site, Murray
Investigational Site, Ingolstadt
Investigational Site, Beverly Hills
Investigational Site, Jerusalem
Investigational Site, Newport Beach
Investigational Site, San Francisco
Investigational Site, Coburg
Investigational Site, Würzburg
Investigational Site, Seattle
Investigational Site, Warwick
Investigational Site, Lübeck
Investigational Site, Maastricht
Investigational Site, Groningen
Investigational Site, Poznan
Investigational Site, Torun
Investigational Site, Krakow
Investigational Site, Warsaw
Investigational Site, Warsaw
Investigational Site, Bialystok
Investigational Site, Gdansk
Investigational Site, Sopot
Investigational Site, Katowice
Investigational Site, Zabrze
Investigational Site, Szczecin
Investigational Site, Lodz
Investigational Site, Warsaw
Investigational Site, Lodz
Investigational Site, London
Lead Sponsor
Gilead Sciences
INDUSTRY